Friday, the U.S. Food and Drug Administration approved Zepbound, the first prescription medication indicated to treat obstructive sleep apnea (OSA) for people with both obesity and moderate to severe OSA. This decision marks a significant milestone for millions of Americans with OSA, particularly those in communities that have historically faced systemic barriers in accessing quality healthcare. Untreated sleep apnea can lead to interruptions in breathing, frequent awakenings during the night, and elevated risks for cardiovascular issues, diabetes, stroke, and even dementia. Although CPAP machines have long been the standard of care, they can be cumbersome and difficult for many patients ...